

Ming-Huang Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8706933/publications.pdf>

Version: 2024-02-01

105
papers

2,187
citations

236925

25
h-index

302126

39
g-index

107
all docs

107
docs citations

107
times ranked

4096
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Patterns and Outcomes in Patients with Esophageal Cancer: An Analysis of a Multidisciplinary Tumor Board Database. <i>Annals of Surgical Oncology</i> , 2022, 29, 572-585.	1.5	9
2	Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study. <i>BMC Cancer</i> , 2022, 22, 55.	2.6	14
3	Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. <i>Cancers</i> , 2022, 14, 218.	3.7	13
4	Regorafenib inhibits epithelial-mesenchymal transition and suppresses cholangiocarcinoma metastasis via YAP1-AREG axis. <i>Cell Death and Disease</i> , 2022, 13, 391.	6.3	4
5	Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. <i>Investigational New Drugs</i> , 2022, 40, 789-797.	2.6	14
6	Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4120-4120.	1.6	0
7	Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4075-4075.	1.6	7
8	Comparison of the Long-term Outcome Between Billroth-I and Roux-en-Y Reconstruction Following Distal Gastrectomy for Gastric Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1955-1961.	1.7	4
9	Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. <i>Biomolecules</i> , 2021, 11, 97.	4.0	6
10	Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. <i>Journal of Biomedical Science</i> , 2021, 28, 29.	7.0	11
11	Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1393-1399.	0.9	13
12	Cardia Gastric Cancer Is Associated With Increased PIK3CA Amplifications and HER2 Expression Than Noncardia Gastric Cancer According to Lauren Classification. <i>Frontiers in Oncology</i> , 2021, 11, 632609.	2.8	1
13	How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?. <i>Cancers</i> , 2021, 13, 3536.	3.7	4
14	Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. <i>Biomedicines</i> , 2021, 9, 885.	3.2	2
15	High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9116.	4.1	9
16	ASO Visual Abstract: Treatment Patterns and Outcomes for Patients with Esophageal Cancer-An Analysis of a Multidisciplinary Tumor Board Database. <i>Annals of Surgical Oncology</i> , 2021, 28, 712-713.	1.5	2
17	Genetic alterations in gastric cancer patients according to sex. <i>Aging</i> , 2021, 13, 376-388.	3.1	9
18	Aldolase A and Phospholipase D1 Synergistically Resist Alkylating Agents and Radiation in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 811635.	2.8	5

#	ARTICLE	IF	CITATIONS
19	Effects of fine particulate matter (PM2.5) on ovarian function and embryo quality in mice. <i>Environment International</i> , 2020, 135, 105338.	10.0	34
20	The clinicopathological characteristics and prognosis of patients with node-positive gastric cancer after curative surgery. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 751-755.	1.4	4
21	Somatic SDHA mutations in paragangliomas in siblings. <i>Medicine (United States)</i> , 2020, 99, e22497.	1.0	3
22	Omics-Based Platforms: Current Status and Potential Use for Cholangiocarcinoma. <i>Biomolecules</i> , 2020, 10, 1377.	4.0	5
23	Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. <i>Vaccines</i> , 2020, 8, 703.	4.4	8
24	Chromosomal Instability May Not Be a Predictor for Immune Checkpoint Inhibitors from a Comprehensive Bioinformatics Analysis. <i>Life</i> , 2020, 10, 276.	2.4	9
25	Pachymic acid protects oocyte by improving the ovarian microenvironment in polycystic ovary syndrome mice. <i>Biology of Reproduction</i> , 2020, 103, 1085-1098.	2.7	5
26	Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. , 2020, 8, e001072.		45
27	Mucinous gastric adenocarcinoma: A good candidate for immune therapy?. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 624-625.	1.4	1
28	The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer. <i>Cancers</i> , 2020, 12, 2318.	3.7	18
29	Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. <i>Frontiers in Oncology</i> , 2020, 10, 561936.	2.8	68
30	Multicentre, phase II study of gemcitabine and Sâ€1 in patients with advanced biliary tract cancer: TG1308 study. <i>Liver International</i> , 2020, 40, 2535-2543.	3.9	7
31	The Clinicopathological Features and Genetic Alterations in Epsteinâ€Barr Virus-Associated Gastric Cancer Patients after Curative Surgery. <i>Cancers</i> , 2020, 12, 1517.	3.7	24
32	Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. <i>Chinese Clinical Oncology</i> , 2020, 9, 7-7.	1.2	4
33	Low but Long-lasting Risk of Reversal of Seroconversion in Patients With Rheumatoid Arthritis Receiving Immunosuppressive Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2573-2581.e1.	4.4	20
34	The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status. <i>Cancers</i> , 2020, 12, 551.	3.7	9
35	Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. <i>Clinical and Translational Immunology</i> , 2020, 9, e1145.	3.8	7
36	The clinicopathological characteristics and genetic alterations of mucinous carcinoma of the stomach. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 141-147.	1.4	10

#	ARTICLE	IF	CITATIONS
37	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. <i>Oncologist</i> , 2020, 25, e782-e788.	3.7	7
38	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	3.7	74
39	<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
40	The clinicopathological characteristics and genetic alterations between younger and older gastric cancer patients with curative surgery. <i>Aging</i> , 2020, 12, 18137-18150.	3.1	7
41	A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors. <i>EJNMMI Research</i> , 2019, 9, 46.	2.5	17
42	Analysis of the clinical significance of DNA methylation in gastric cancer based on a genome-wide high-resolution array. <i>Clinical Epigenetics</i> , 2019, 11, 154.	4.1	9
43	mTOR Inhibitors in Advanced Biliary Tract Cancers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 500.	4.1	23
44	<p>Interferon α-inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival<p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 1893-1905.	1.9	21
45	Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without <i>Helicobacter pylori</i> Infection. <i>Oncologist</i> , 2019, 24, e845-e853.	3.7	24
46	Deltex1 suppresses T cell function and is a biomarker for diagnosis and disease activity of systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 719-728.	1.9	5
47	Overéexpression of TNNI3K is associated with earlyéstage carcinogenesis of cholangiocarcinoma. <i>Molecular Carcinogenesis</i> , 2019, 58, 270-278.	2.7	6
48	Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1534-1542.	3.7	15
49	Genomic profiling for unfavorable carcinoma of unknown primary patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e13140-e13140.	1.6	0
50	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4101-4101.	1.6	1
51	Refractory hypercalcemia due to hyperparathyroidism in a patient with metastatic parathyroid carcinoma. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 84-87.	0.2	4
52	The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 593-598.	1.4	4
53	Transcriptome analysis and prognosis of ALDH isoforms in human cancer. <i>Scientific Reports</i> , 2018, 8, 2713.	3.3	26
54	Toxicities, safeties and clinical response of dacarbazine-based chemotherapy on neuroendocrine tumors in Taiwan population. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 423-428.	1.4	1

#	ARTICLE	IF	CITATIONS
55	MART-10, a 1 β ,25(OH) ₂ D ₃ Analog, Potently Represses Metastasis of ER ⁺ Breast Cancer Cells with VEGF-A Overexpression. <i>Anticancer Research</i> , 2018, 38, 3879-3887.	1.1	9
56	Nab [®] paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. <i>Oncology Letters</i> , 2018, 16, 566-572.	1.8	11
57	MET ⁺ RON dual inhibitor, BMS [®] 777607, suppresses cholangiocarcinoma cell growth, and MET ⁺ RON upregulation indicates worse prognosis for intra [®] hepatic cholangiocarcinoma patients. <i>Oncology Reports</i> , 2018, 40, 1411-1421.	2.6	4
58	Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients undergoing Biologics Treatment. <i>Journal of Infectious Diseases</i> , 2017, 215, jiw606.	4.0	51
59	Glucose transporter 4 promotes head and neck squamous cell carcinoma metastasis through the TRIM24-DDX58 axis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 11.	17.0	41
60	Evaluation of prognostic factors and implication of lymph node dissection in intrahepatic cholangiocarcinoma: 10-year experience at a tertiary referral center. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 140-146.	1.4	14
61	Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study. <i>Head and Neck</i> , 2017, 39, 1333-1342.	2.0	8
62	Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells. <i>Journal of Molecular Medicine</i> , 2017, 95, 965-975.	3.9	16
63	EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells. <i>European Journal of Cancer</i> , 2017, 72, 112-123.	2.8	35
64	The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. <i>Experimental and Molecular Medicine</i> , 2017, 49, e366-e366.	7.7	29
65	Comparison of the surgical outcomes of minimally invasive and open surgery for octogenarian and older compared to younger gastric cancer patients: a retrospective cohort study. <i>BMC Surgery</i> , 2017, 17, 68.	1.3	17
66	Advances in Laparoscopic and Robotic Gastrectomy for Gastric Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 13-17.	1.9	17
67	A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. <i>Oncotarget</i> , 2017, 8, 44121-44130.	1.8	53
68	Comparative study of the 7th and 8th AJCC editions for gastric cancer patients after curative surgery. <i>PLoS ONE</i> , 2017, 12, e0187626.	2.5	18
69	Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis. <i>Molecular Cancer</i> , 2017, 16, 135.	19.2	59
70	Clinical relevance of cell-free DNA in gastrointestinal tract malignancy. <i>Oncotarget</i> , 2017, 8, 3009-3017.	1.8	38
71	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. <i>Oncotarget</i> , 2017, 8, 41294-41304.	1.8	33
72	Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. <i>Oncotarget</i> , 2017, 8, 103613-103625.	1.8	17

#	ARTICLE	IF	CITATIONS
73	Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. <i>Oncotarget</i> , 2017, 8, 113444-113459.	1.8	19
74	Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors. <i>International Journal of Biological Sciences</i> , 2016, 12, 1523-1532.	6.4	31
75	Clinical significance of circulating plasma DNA in gastric cancer. <i>International Journal of Cancer</i> , 2016, 138, 2974-2983.	5.1	68
76	Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. <i>Scientific Reports</i> , 2016, 6, 25369.	3.3	21
77	The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 396-402.	1.1	12
78	A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma. <i>Medicine (United States)</i> , 2016, 95, e2565.	1.0	0
79	ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients. <i>Clinical Cancer Research</i> , 2016, 22, 4225-4235.	7.0	44
80	MART-10, the new brand of 1 α ,25(OH) $_2$ D $_3$ analog, is a potent anti-angiogenic agent in vivo and in vitro. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 26-34.	2.5	9
81	Mutations in PI3K/AKT pathway genes and amplifications of <i>PIK3CA</i> are associated with patterns of recurrence in gastric cancers. <i>Oncotarget</i> , 2016, 7, 6201-6220.	1.8	61
82	Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. <i>Oncotarget</i> , 2016, 7, 9135-9149.	1.8	43
83	Extrahepatic cancer risk among patients with liver cirrhosis in Taiwan: A nationwide population-based study. <i>Journal of Clinical Oncology</i> , 2016, 34, 1564-1564.	1.6	1
84	A Prognostic Nomogram for Overall Survival of Patients After Hepatectomy for Intrahepatic Cholangiocarcinoma. <i>Anticancer Research</i> , 2016, 36, 4249-58.	1.1	15
85	Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1077-1084.	0.8	18
86	Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	11
87	Upregulation of BMP-2 expression in peripheral blood mononuclear cells by proinflammatory cytokines and radiographic progression in ankylosing spondylitis. <i>Modern Rheumatology</i> , 2015, 25, 913-918.	1.8	17
88	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. <i>Annals of Oncology</i> , 2015, 26, 943-949.	1.2	130
89	High neuroendocrine component is a factor for poor prognosis in gastrointestinal high-grade malignant mixed adenoneuroendocrine neoplasms. <i>Journal of the Chinese Medical Association</i> , 2015, 78, 454-459.	1.4	26
90	E-TPF (cetuximab, cisplatin, docetaxel, 5-FU) induction chemotherapy in locally advanced squamous cell carcinoma of oral cavity: A phase II study. <i>Journal of Clinical Oncology</i> , 2015, 33, e17016-e17016.	1.6	1

#	ARTICLE	IF	CITATIONS
91	A Nation-Wide Cancer Registry-Based Study of Adenosquamous Carcinoma in Taiwan. PLoS ONE, 2015, 10, e0139748.	2.5	9
92	DDX3 as a strongest prognosis marker and its downregulation promotes metastasis in colorectal cancer. Oncotarget, 2015, 6, 18602-18612.	1.8	47
93	Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. Oncotarget, 2015, 6, 23594-23608.	1.8	15
94	Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment. BioMed Research International, 2014, 2014, 1-7.	1.9	31
95	Lung involvement in primary Sjögren's syndrome: Correlation between high-resolution computed tomography score and mortality. Journal of the Chinese Medical Association, 2014, 77, 75-82.	1.4	25
96	Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma. Oncotarget, 2014, 5, 2372-2389.	1.8	58
97	Gene expression-based chemical genomics identifies heat shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma. Cancer, 2013, 119, 293-303.	4.1	31
98	Expression of GOLM1 Correlates with Prognosis in Human Hepatocellular Carcinoma. Annals of Surgical Oncology, 2013, 20, 616-624.	1.5	23
99	Expression of gremlin 1 correlates with increased angiogenesis and progression-free survival in patients with pancreatic neuroendocrine tumors. Journal of Gastroenterology, 2013, 48, 101-108.	5.1	30
100	Gene Expression-Based Chemical Genomics Identifies Potential Therapeutic Drugs in Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e27186.	2.5	58
101	Prolonged facial edema is an indicator of poor prognosis in patients with head and neck squamous cell carcinoma. Supportive Care in Cancer, 2010, 18, 1313-1319.	2.2	24
102	Prognostic significance of a pretreatment hematologic profile in patients with head and neck cancer. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1783-1790.	2.5	52
103	High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma. Annals of Hematology, 2008, 87, 475-480.	1.8	92
104	Comparison of Myeloablative and Nonmyeloablative Hematopoietic Stem Cell Transplantation for Treatment of Chronic Myeloid Leukemia. International Journal of Hematology, 2007, 86, 275-281.	1.6	6
105	The clinicopathological characteristics and genetic alterations of gastric cancer patients according to the Lauren classification. International Surgery, 0, , .	0.1	1